A modified human ELISPOT assay to defect specific responses to primary tumor cell targets

Journal of Translational Medicine

Volumn 2, Issue , 2004, Pages

  Malyguine, Anatoli ^a   Strobl, Susan L ^a   Shafer Weaver, Kimberly A ^a   Ulderich, Tracy ^a   Troke, Angela ^a   Baseler, Michael ^a   Kwak, Larry W ^b   Neelapu, Sattva S ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; GAMMA INTERFERON; TUMOR ANTIGEN;

ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CANCER PATIENT; CELL ISOLATION; CELL SPECIFICITY; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNODETECTION; IMMUNOREACTIVITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROCESS OPTIMIZATION; RELIABILITY; REPRODUCIBILITY; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; TARGET CELL; THEORETICAL MODEL; TUMOR CELL; TUMOR IMMUNITY;

EID: 4344560286     PISSN: 14795876     EISSN: None     Source Type: Journal    
DOI: 10.1186/1479-5876-2-9     Document Type: Article

References (17)

1. Rosenberg S: Progress in human tumor immunology and immunotherapy. Nature 2001, 411:380-384.
2. Wang R, Rosenberg S: Human tumor antigens for cancer vaccine development. Immunol Rev 1999, 170:85-100.
3. Kwak L: Translational development of active immunotherapy for hematologic malignancies. Semin Oncol 2003, 30(3 Suppl 8):17-22.
4. Keilholz U, Weber J, Finke J, Gabrilovich D, Kast W, Disis M, Kirkwood J, Scheibenbogen C, Schlom J, Maino V, Lyerly H, Lee P, Storkus W, Marincola F, Worobec A, Atkins M: Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002, 25:97-138.
5. Whiteside T: Immunologic monitoring of clinical trials in patients with cancer: technology versus common sense. Immunol Invest 2000, 29:149-162.
6. Schmittel A, Keilholz U, Thiel E, Scheibenbogen C: Quantification of tumor-specific T lymphocytes with the ELISPOT assay. J Immunother 2000, 23:289-295.
7. Peterson A, Harlin H, Gajewski T: Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 2003, 21:2342-2348.
8. Asai T, Storkus W, Mueller-Berghaus J, Knapp W, DeLeo A, Chikamatsu K, Whiteside T: In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins. Cancer Immun 2002, 2:3.
9. Meidenbauer N, Harris D, Spitler L, Whiteside T: Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 2000, 43:88-100.
10. Bendandi M, Gocke C, Kobrin C, Benko F, Sternas L, Pennington R, Watson T, Reynolds C, Gause B, Duffy P, Jaffe E, Creekmore S, Longo D, Kwak L: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999, 5:1171-1177.
11. Kwak L, Pennington R, Boni L, Ochoa A, Robb R, Popescu M: Cutting Edge: Liposomal formulation of a self lymphoma antigen induces potent protective anti-tumor immunity. J Immunol 1998, 160:3637-3461.
12. Schultze J, Cardoso A, Freeman G, Seamon M, Daley J, Pinkus G, Gribben J, Nadler L: Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 1995, 92:8200-8204.
13. Nuchtern J, Biddison W, Klausner R: Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature 1990, 343:74-76.
14. Sant A: Endogenous antigen presentation by MHC class II molecules. Immunol Res 1994, 13:253-267.
15. Maecker H, Dunn H, Suni M, Khatamzas E, Pitcher C, Bunde T, Persaud N, Trigona W, Fu T, Sinclair E, Bredt B, McCune J, Maino V, Kern F, Picker L: Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 2001, 255:27-40.
16. Lally K, Mocellin S, Ohnmacht G, Nielsen M, Bettinotti M, Panelli M, Monsurro V, Marincola F: Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int J Cancer 2001, 93:841-847.
17. Disis M, Gooley T, Rinn K, Davis D, Piepkorn M, Cheever M, Knutson K, Schiffman K: Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002, 20:2624-2632.